Израиль -
иврит -
Ministry of Health
aeriseal emphysematous lung sealant system, - aeiseal system
ציטרוס בע"מ - מומחה - to reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema
Израиль -
иврит -
Ministry of Health
aeriseal emphysematous lung sealant system, - aeiseal system
a.m.i. technologies, ltd. - מומחה - to reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema
Израиль -
иврит -
Ministry of Health
system for measurement of vascular access blood flow and cardiac output, and accessories
טבע מדיקל (שיווק) בע"מ - אחות - the aureflo monitor is intended for use with transonic systems’ ht300-series-ft surgical flowmeters. these flowmeters are intended for use with adult and pediatric patients for measurement of blood or liquid volume flow with transonic perivascular flowprobes
Израиль -
иврит -
Ministry of Health
אמיודקור זריקות
sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.
Израиль -
иврит -
Ministry of Health
וי-דלגין סירופ מרוכז למבוגרים
vitamed pharmaceutical industries ltd - dipyrone - סירופ - dipyrone 1.25 g / 5 ml - pyrazolones - relief of moderate to severe pain as in headache, toothache, dysmenorrhea andfor high fever that does not respond to other measures.
Израиль -
иврит -
Ministry of Health
ארומזין
pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.